Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Forward-looking disclosure covers 2026 full-year and third-quarter adjusted diluted EPS guidance.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Forward-looking disclosure covers 2026 full-year and third-quarter adjusted diluted EPS guidance
- Apogee acquisition benefits and integration expected to influence adjusted diluted EPS
- Pipeline focus includes zumilokibart (APG777) and APG273 development, regulatory progress, and commercial potential
- Key risks include integration costs, clinical-trial failure, intellectual-property challenges, competition, and regulatory action
Item EX-99.1 · Exhibit EX-99.1
- Apogee acquisition completed for $135.11 per share in cash, valuing equity at approximately $10.9 billion
- Pipeline adds late-stage zumilokibart for atopic dermatitis and APG273 for asthma, strengthening AbbVie’s immunology growth strategy
- Acquisition expected to reduce adjusted EPS by $0.14 in 2026 and approximately $0.46 in 2027, with accretion beginning in 2032
- 2026 adjusted EPS guidance reaffirmed at $13.87-$14.07, including the acquisition’s $0.14 dilution
- Apogee shares ceased NASDAQ trading on Sept. 3, 2026, following transaction completion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.